acute stroke patient News
-
A new SIMAD’s C-arm join the Stroke Unit of Neurology in Modena, Italy
The Ramazzini hospital in Carpi (Modena, Italy) has chosen a SIMAD mobile C-arm to be part of the Stroke Unit dedicated to the surveillance and treatment of acute stroke patients. The Department of Neurology of this italian hospital has chosen a model that combines the performance of a typical “dual” system (c-arm + monitor cart) with the versatility of a compact system, thus ...
By SIMAD s.r.l.
-
BrainQ announces encouraging study results for new therapy to reduce disability after stroke
JERUSALEM, March 11, 2021 -- BrainQ, the Israeli start-up with an AI-powered therapeutic platform, today revealed the encouraging results of their Randomized Controlled Trial (RCT) which supported a recently granted request for FDA Breakthrough Device Designation. The pilot trial data will be presented as part of the International Stroke Conference between March 17-19. In a single site, the ...
-
Lumosa One of the Finalists for Clinical Advance of the Year Award in Scrip Awards 2022
We are delighted to announce that Lumosa's LT3001 (odatroltide) has been shortlisted for the "Clinical Advance of the Year Award" at this year's Pharma Intelligence Scrip Awards. This Award seeks to recognize success in a clinical trial of a new drug product (biological or chemical) that is expected to lead to an advance in healthcare. Other finalists include Boehringer Ingelheim and Eli Lilly's ...
-
Neuros Medical Appoints Tom Wilder as President and CEO
Neuros Medical, Inc., a neuromodulation company, announced today the appointment of Tom Wilder as President and CEO. Mr. Wilder has over 30 years of experience, having most recently led Sequent Medical, Inc., a neurovascular company that developed the WEB Aneurysm Embolization System, where he served for six years. Sequent was acquired by Terumo Corporation in 2016 for up to $380 million. Prior ...
-
Sonothrombolysis IPDM chosen as the September 2021 Paper of the Month by the European Stroke Organization
The European Stroke Organization has chosen “Sonothrombolysis in Patients With Acute Ischemic Stroke With Large Vessel Occlusion: An Individual Patient Data Meta-Analysis” for the September 2021 “Paper of the ...
-
Sonothrombolysis in Patients With Acute Ischemic Stroke With Large Vessel Occlusion: An Individual Patient Data Meta-Analysis Has Been Published
Stroke has published “Sonothrombolysis in Patients With Acute Ischemic Stroke With Large Vessel Occlusion: An Individual Patient Data Meta-Analysis”. This meta-analysis uses individual patient data from 7 different randomized controlled trials, including the CLOTBUST-ER trial, to show that “Sonothrombolysis was associated with a nearly 2-fold increase in the odds of complete ...
-
Blogpost - Scientific proof of the effectiveness of the REAplan
Robot-assisted therapy (RAT) is of significant interest in early rehabilitation, when neuroplasticity is high but motor control is frequently insufficient for patients to independently practice functional movements. Many patients with stroke experience persistent upper limb (UL) impairments. This single-blind, randomized, controlled trial[i] explored the impact of partially substituting ...
By Axinesis
-
Imperative Care Announces U.S. Clearance of the ZOOM Aspiration System
Imperative Care, Inc., a company singularly dedicated to answering unsolved problems in stroke, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s ZOOM™ Aspiration System – a family of products designed to facilitate clot removal during ischemic stroke. The ZOOM Aspiration System includes the ZOOM Reperfusion Catheters, ZOOM Aspiration ...
-
Imperative Care Announces First Patient Enrolled in the Imperative Trial Evaluating the Zoom 88 Large Distal Platform for the Treatment of Ischemic Stroke
Imperative Care, Inc. announced today that the first patient has been enrolled in the Imperative Trial. This prospective, multi-center clinical trial is the first study designed to evaluate the clinical benefits of direct aspiration for the treatment of ischemic stroke with the Zoom 88 Large Distal Platform, which is currently FDA cleared for neurovascular access. Additionally, the trial will ...
-
Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries Asundexian is being evaluated as a potential improved treatment option in stroke prevention and could be part of an entirely new class of treatment options in thrombosis management that aims to uncouple efficacy from ...
By Bayer AG
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you